Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is a male or female between 30 and 65 years of age (inclusive) at the pre-study (screening)~* Female participant of childbearing potential must have a negative pregnancy test~* Participant has a brachial systolic blood pressure \>130 mm Hg~and \<180 mm Hg~* Participant has a Body Mass Index (BMI) that is \>20 kg/m\^2 and \<35 kg/m\^2~* Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months~Exclusion Criteria:~* Female Participant is pregnant or lactating~* Participant anticipates the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) other than acetaminophen~* Participant is currently a user (including recreational use) of any illicit drugs, has a history of drug or alcohol abuse within approximately 2 years, or has a positive prestudy urine drug screen~* Participant has a condition for which there is a warning, contraindication, or precaution against the use of ISMN ER including: acute myocardial infarction or congestive heart failure, hypotension, volume depletion, and pregnancy~* Participant has a history of significant drug allergy or any clinically significant adverse experience of a serious nature related to the administration of either a marketed or an investigational drug, including nitrates, nitrites, Amlodipine, and ISMN ER

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo/ISMN ER/Amlodipine (Sequence 1) (Type: EXPERIMENTAL): Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
- ISMN ER/Amlodipine/Placebo (Sequence 2) (Type: EXPERIMENTAL): Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
- Amlodipine/Placebo/ISMN ER (Sequence 3) (Type: EXPERIMENTAL): Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
- ISMN ER/Placebo/Amlodipine (Sequence 4) (Type: EXPERIMENTAL): Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
- Placebo/Amlodipine/ISMN ER (Sequence 5) (Type: EXPERIMENTAL): Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
- Amlodipine/ISMN ER/Placebo (Sequence 6) (Type: EXPERIMENTAL): Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.

Based on this trial design, predict the completion outcome and termination type (if applicable).